Navigation Links
Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting

MADISON, Wis., March 2 /PRNewswire/ -- Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

The workshop, entitled "Toxicology in the 21st Century: Stem Cells in Drug Discovery and Development," will present the current understanding of pluripotent stem cells and their utility in providing cellular models, how they are being employed to understand pharmaceutical mechanisms of efficacy and toxicity, and the practical issues and obstacles that will need to be addressed to enable regenerative cellular therapy to become a reality. Widely regarded as the father of stem cell research, Dr. James Thomson, CDI Chief Scientific Officer and Director of Regenerative Biology at the Morgridge Institute for Research, University of WisconsinMadison, will discuss his predictions on the impact of induced pluripotent stem cells (iPSCs) on personalized therapeutics during the panel discussion.

"iPSC-derived human cells are a very promising approach to drug discovery and toxicology testing and have many advantages over current cell models," said Chris Parker, chief commercial officer of CDI and co-chairperson of the workshop.  "We organized this workshop, in collaboration with one of our customers, Roche, to present the iPSC-based cell model to the pharmaceutical toxicology community."

The presentation schedule:

  • Human Inducible Pluripotent Stem Cell Derived In Vitro Models – the Path to a Better Understanding of Individual Biology and Their Utility in Drug Discovery and Development, Chris Parker, CDI, Madison, WI
  • Application of Stem Cell-Derived Cardiomyocytes in Toxicology and Safety Pharmacology, Kyle Kolaja, Roche, Nutley, NJ
  • Pharmaceutical Perspectives on Introduction of Regenerative Medicine Concepts into the Existing Pharmaceutical Paradigm, Ruth McKernan, Pfizer, Groton, CT
  • Developing Stem Cell-Based Therapies: FDA Product and Preclinical Regulatory Considerations, Mercedes Serabian, U.S. FDA, Silver Spring, MD
  • How the Understanding of the Biology of Inducible Pluripotent Stem Cells Will Evolve: Predictions on Methods of Stem Cell Induction and the Impact on Cell-Based Therapy, James Thomson, University of Wisconsin, Madison, WI

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D ($9.1B US). The Group posted sales of 49.1 billion Swiss francs ($45.1B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications.  CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools.  In addition, it is the leader in iPS technology, the production of pluripotent stem cell lines from adult tissue.  CDI was founded in 2004 by James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund.  CDI's facilities are located in Madison, Wisconsin.  See

SOURCE Cellular Dynamics International

Back to top



SOURCE Cellular Dynamics International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
3. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
4. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
5. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
6. Cellular construction methods emulated
7. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
8. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
9. New insights into cellular reprogramming revealed by genomic analysis
10. Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
11. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
Post Your Comments:
(Date:6/27/2016)... -- Alex,s Lemonade Stand Foundation (ALSF), a leading national childhood ... state-of-the-art bioinformatics lab, using ,big data, to advance the ... Liz Scott , co-executive director of ALSF and ... Washington, D.C. , hosted by Vice ... of pediatric cancer research and awareness. ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):